3-溴异恶唑-5-甲酸 | 6567-35-7

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机卤素化合物 - 芳基卤化物
• 中文名称: 3-溴异恶唑-5-甲酸
• 中文别名: 3-溴异噁唑-5-羧酸；3-溴异VA唑-5-羧酸
• 英文名称: 3-bromo-5-isoxazolecarboxylic acid
• 英文别名: 3-bromoisoxazole-5-carboxylic acid；3-Bromo-5-carboxyisoxazole；3-bromo-isoxazole-5-carboxylic acid；3-Brom-isoxazol-carbonsaeure-(5)；3-bromo-1,2-oxazole-5-carboxylic acid
• CAS: 6567-35-7
• 化学式: C₄H₂BrNO₃
• 分子量: 191.969
• InChiKey: YNIMFLBFJCGBQK-UHFFFAOYSA-N

物化性质

• 熔点：
  170-175 °C
• 沸点：
  375.2±27.0 °C(Predicted)
• 密度：
  2.038±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63.3
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Bromoisoxazole-5-carboxylic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Bromoisoxazole-5-carboxylic acid
CAS number: 6567-35-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C4H2BrNO3
Molecular weight: 192

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-溴异恶唑-5-甲酸 在 草酰氯 作用下， 生成 3-bromo-5-isoxazolecarboxylic acid chloride
  参考文献：
  名称：

  低细胞毒性的有效和共价HER-2酪氨酸激酶抑制剂的设计，合成和生物学研究

  摘要：

  本文介绍了用于治疗HER2阳性乳腺癌的新型HER-2酪氨酸激酶抑制剂的发现和开发。EGFR家族已被认为是癌症进展中的关键冥想分子。HER-2酪氨酸激酶是其中的成员之一。为了探索有效的HER-2抑制剂，已经设计，合成和评估了一系列新的4-苯胺基-3-氰基喹啉衍生物。大多数化合物对SK-BR-3细胞系和HER-2激酶具有适度的增殖抑制作用。化合物16似乎是最有效的化合物（HER-2激酶的IC 50：19.4纳米，SK-BR-3的IC 50：94纳米）。在细胞毒性实验中，化合物16在Beas-2b细胞系（人支气管上皮细胞）上显示出比neratinib低得多的细胞毒性。总之，化合物16将是进一步开发抗乳腺癌药物的有前途的先导化合物。

  DOI：

  10.1007/s11696-019-00686-0
• 作为产物：
  描述：

  3-溴-5-异噁唑羧酸甲酯 在 lithium hydroxide 作用下， 以 四氢呋喃 为溶剂， 反应 5.0h， 以57.7%的产率得到3-溴异恶唑-5-甲酸
  参考文献：
  名称：

  低细胞毒性的有效和共价HER-2酪氨酸激酶抑制剂的设计，合成和生物学研究

  摘要：

  本文介绍了用于治疗HER2阳性乳腺癌的新型HER-2酪氨酸激酶抑制剂的发现和开发。EGFR家族已被认为是癌症进展中的关键冥想分子。HER-2酪氨酸激酶是其中的成员之一。为了探索有效的HER-2抑制剂，已经设计，合成和评估了一系列新的4-苯胺基-3-氰基喹啉衍生物。大多数化合物对SK-BR-3细胞系和HER-2激酶具有适度的增殖抑制作用。化合物16似乎是最有效的化合物（HER-2激酶的IC 50：19.4纳米，SK-BR-3的IC 50：94纳米）。在细胞毒性实验中，化合物16在Beas-2b细胞系（人支气管上皮细胞）上显示出比neratinib低得多的细胞毒性。总之，化合物16将是进一步开发抗乳腺癌药物的有前途的先导化合物。

  DOI：

  10.1007/s11696-019-00686-0

文献信息

• 2(3H)-Oxazolone durch Photoumlagerung von 3-Hydroxyisoxazolen. Synthese von Muscazon
  作者：H. Göth、A. R. Gagneux、C. H. Eugster、H. Schmid

  DOI：10.1002/hlca.19670500121

  日期：——

  3-Hydroxyisoxazole, für die ein allgemeines Herstellungsverfahren angegeben wird, lassen sich durch UV.-Bestrahlung in 2(3H)-Oxazolone überführen.

  3-羟基异恶唑，在所有化合物中起作用，在2（3 H）中的Bestrahlung在2（3 H）中形成-恶唑啉酮überführen。
• [EN] AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS AZAINDAZOLE EN TANT QU'ANTAGONISTES DES RÉCEPTEURS CCR1
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2010036632A1

  公开（公告）日：2010-04-01

  Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are methods of making and methods of using same.

  公开的是化合物的公式（I），用于治疗通过CCR1活性介导或维持的多种疾病和疾病，包括自身免疫性疾病，如风湿性关节炎和多发性硬化症。还公开了制备方法和使用方法。
• Sulfamylurea hypoglycemic agents. 6. High-potency derivatives
  作者：Reinhard Sarges、Donald E. Kuhla、Hans E. Wiedermann、Dale A. Mayhew

  DOI：10.1021/jm00227a023

  日期：1976.5

  Synthetic methods for a series of novel sulfamylurea derivatives have been developed. The hypoglycemic activity of simple 1-piperidinosulfonylureas is greatly enhanced by attaching an acylaminoethyl function in the 4 position of the piperidine ring. Optimum activity is achieved when the acyl radical is 5-chloro-2-methoxybenzoyl, 2-methoxynicotinyl, 5-chloro-2-methoxynicotinyl, 1,2-dihydro-1-methyl-2-ketonicotinyl

  已经开发了一系列新的氨磺酰脲衍生物的合成方法。通过在哌啶环的4位连接一个酰基氨基乙基官能团，可以大大增强简单的1-哌啶子基磺酰脲类的降血糖活性。当酰基是5-氯-2-甲氧基苯甲酰基，2-甲氧基烟碱，5-氯-2-甲氧基烟碱，1,2-二氢-1-甲基-2-酮丁炔基，2,3-乙二氧基苯甲酰基，喹啉时，可获得最佳活性。 -8-羰基或6-氯喹啉-8-羰基。末端尿素氮上的最佳取代基是环己基，双环庚烯基甲基，在某些情况下是丙基，7-氧杂双环庚基甲基和金刚烷基。发现这些化合物之一（81，gliamilide）在人体中具有良好的耐受性，并且血浆半衰期非常短。
• Structure−Activity Studies of 6-Substituted Decahydroisoquinoline-3-carboxylic Acid AMPA Receptor Antagonists. 2. Effects of Distal Acid Bioisosteric Substitution, Absolute Stereochemical Preferences, and in Vivo Activity
  作者：Paul L. Ornstein、M. Brian Arnold、Nancy K. Allen、Thomas Bleisch、Peter S. Borromeo、Charles W. Lugar、J. David Leander、David Lodge、Darryle D. Schoepp

  DOI：10.1021/jm950913h

  日期：1996.1.1

  the excitatory amino acid antagonist activity in a series of decahydroiso-quinoline-3-carboxyic acids, and within this series found the potent and selective AMPA antagonist (3SR,4aRS,6RS,8aRS)-6-(2-(1H-tetrazol-5-yl )ethyl) decahydroisoquinoline-3-carboxylic acid (1). In this and the preceding paper, we looked at the structure-activity relationships for AMPA antagonist activity in this series of compounds

  我们探索了一系列十氢异喹啉-3-羧酸中的兴奋性氨基酸拮抗剂活性，并在该系列中发现了有效的选择性AMPA拮抗剂（3SR，4aRS，6RS，8aRS）-6-（2-（1H -四唑-5-基）乙基）十氢异喹啉-3-羧酸（1）。在本文中，我们研究了该系列化合物中AMPA拮抗剂活性的构效关系。我们已经表明1具有最佳的立体化学阵列，并且AMPA拮抗剂活性对于将四唑与双环核分开的二碳间隔基而言是最大的。在本文中，我们探讨了改变远端酸的作用以及许多类似物的绝对立体化学偏好。我们研究了各种不同的酸性生物异构体，包括五元杂环酸，例如四唑，1,2,4-三唑和3-异恶唑酮；羧酸，膦酸和磺酸；和酰基磺酰胺。对大鼠皮质组织中的化合物抑制AMPA（[3H] AMPA），NMDA（[3H] CGS 19755）和海藻酸（[3H] kainic acid）受体选择性放射性配体结合的能力及其功能进行了评估抑制由AMPA（40 microM），NMDA（40
• SUBSTITUTED BENZIMDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS
  申请人：PLAYER Mark R.

  公开号：US20120202856A1

  公开（公告）日：2012-08-09

  The present invention is directed to benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by TRP M8, including for example, inflammatory pain, inflammatory hyperalgesia, inflammatory hypersensitivity condition, neuropathic pain, neuropathic cold allodynia, inflammatory somatic hyperalgesia, inflammatory visceral hyperalgesia, cardiovascular disease aggravated by cold and pulmonary disease aggravated by cold.

  本发明涉及苯并咪唑衍生物，包含它们的药物组合物以及它们在治疗由TRP M8调节的疾病和症状中的应用，例如炎症性疼痛、炎症性过敏症、炎症性过敏性疾病、神经病性疼痛、神经性寒冷触痛、炎症性体部过敏症、炎症性内脏过敏症、受冷加重的心血管疾病和受冷加重的肺部疾病。